Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Bejon

Showing results (241-250 of 276) with videos related to

Pageof 28
Sort By:
Science (New York, N.Y.)|October 7, 2021
COVID-19 transmission dynamics underlying epidemic waves in KenyaSamuel P C Brand, John Ojal, Rabia Aziza, et al.
Science Advances|September 14, 2019
The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremiaJohn Muthii Muriuki, Alexander J Mentzer, Gavin Band, et al.
Health Technology Assessment (Winchester, England)|August 3, 2019
Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCTMatthew Scarborough, Ho Kwong Li, Ines Rombach, et al.
Elife|June 14, 2022
Transmission networks of SARS-CoV-2 in Coastal Kenya during the first two waves: A retrospective genomic studyCharles N Agoti, Lynette Isabella Ochola-Oyier, Simon Dellicour, et al.
Plos One|March 26, 2013
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsCaroline Ogwang, Muhammed Afolabi, Domtila Kimani, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Frontiers in Microbiology|January 8, 2015
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionSusanne H Hodgson, Elizabeth Juma, Amina Salim, et al.
Medrxiv : the Preprint Server for Health Sciences|June 10, 2025
<i>OSBPL11</i> is an African-specific locus associated with 25-hydroxyvitamin D concentrations and cardiometabolic healthReagan M Mogire, John Muthii Muriuki, Ruth Fiona Bayimenye, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.
PLOS Global Public Health|March 24, 2023
SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021Anthony O Etyang, Ifedayo Adetifa, Richard Omore, et al.
Pageof 28

Showing results (241-250 of 276) with videos related to

Sort By:
Pageof 28
Science (New York, N.Y.)|October 7, 2021
COVID-19 transmission dynamics underlying epidemic waves in KenyaSamuel P C Brand, John Ojal, Rabia Aziza, et al.
Science Advances|September 14, 2019
The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremiaJohn Muthii Muriuki, Alexander J Mentzer, Gavin Band, et al.
Health Technology Assessment (Winchester, England)|August 3, 2019
Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCTMatthew Scarborough, Ho Kwong Li, Ines Rombach, et al.
Elife|June 14, 2022
Transmission networks of SARS-CoV-2 in Coastal Kenya during the first two waves: A retrospective genomic studyCharles N Agoti, Lynette Isabella Ochola-Oyier, Simon Dellicour, et al.
Plos One|March 26, 2013
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsCaroline Ogwang, Muhammed Afolabi, Domtila Kimani, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Frontiers in Microbiology|January 8, 2015
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionSusanne H Hodgson, Elizabeth Juma, Amina Salim, et al.
Medrxiv : the Preprint Server for Health Sciences|June 10, 2025
<i>OSBPL11</i> is an African-specific locus associated with 25-hydroxyvitamin D concentrations and cardiometabolic healthReagan M Mogire, John Muthii Muriuki, Ruth Fiona Bayimenye, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.
PLOS Global Public Health|March 24, 2023
SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021Anthony O Etyang, Ifedayo Adetifa, Richard Omore, et al.
Pageof 28